Axiolabs
Axiolabs
Ipamorelin 5 mg
Product Information Compound Details
Active Substance Ipamorelin Selective Growth Hormone Secretagogue
5 mg/vialStrength 5 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Peptide Type Growth Hormone Secretagogue
Drug Class Research Peptide
Manufacturer Axiolabs
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Ipamorelin 5 mg by Axiolabs
Ipamorelin 5 mg is a lyophilized research peptide manufactured by Axiolabs containing Ipamorelin at 5 mg per vial, supplied as a powder for reconstitution in a 2 mL vial.
Ipamorelin Injectable
Ipamorelin 5 mg contains the synthetic pentapeptide ipamorelin, a selective growth hormone secretagogue originally developed by Novo Nordisk. It acts as a ghrelin receptor (GHS-R1a) agonist, stimulating endogenous growth hormone release from the pituitary gland in a pulsatile manner that more closely resembles natural physiological secretion than exogenous HGH administration.
In medical research, ipamorelin was investigated in clinical trials for postoperative ileus, a condition involving delayed gastrointestinal recovery after surgery. The compound demonstrated a numerical improvement in time to first tolerated meal but did not meet its efficacy endpoints, and development in this indication was discontinued. No FDA-approved human product exists for ipamorelin, and the FDA has recommended against its use in compounded drug products due to safety concerns.
In non-medical bodybuilding contexts, ipamorelin is commonly referenced for its selective GH-releasing properties, with users reporting benefits for recovery, body composition, and sleep quality. Its appeal lies in its selectivity: unlike older growth hormone secretagogues such as GHRP-6, ipamorelin does not meaningfully elevate cortisol, prolactin, or appetite at standard research doses. Such use falls outside approved indications.
Key Properties of Ipamorelin 5 mg
- Selective ghrelin receptor agonist stimulating pulsatile GH release
- Does not meaningfully elevate cortisol or prolactin at typical doses
- No significant appetite stimulation compared to GHRP-6
- 5 mg per vial allows flexible reconstitution for research protocols
- One of the most commonly referenced GH secretagogues in research settings
Formulation
Lyophilized Powder
Ipamorelin 5 mg is supplied as a lyophilized powder in a 2 mL vial. Lyophilization preserves peptide stability during storage and transport. The powder requires reconstitution with an appropriate solvent before experimental use.
Product Profile
Ipamorelin Profile
Ipamorelin is a selective growth hormone secretagogue that stimulates pituitary GH release through ghrelin receptor agonism, with a notably clean side-effect profile compared to older GHRPs.
Selective Growth Hormone Secretagogue
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor targeted by ghrelin. By activating this receptor on pituitary somatotrophs, ipamorelin stimulates the release of endogenous growth hormone in a pulsatile fashion.
The compound was first described in a 1998 paper by Raun and colleagues, who characterized it as the first selective growth hormone secretagogue. Unlike GHRP-6 and GHRP-2, ipamorelin does not significantly stimulate cortisol, prolactin, or ACTH release at doses that produce GH secretion. This selectivity has made it a preferred research peptide for investigators studying GH axis modulation without the hormonal "noise" associated with older compounds.
Human efficacy data for GH-related endpoints is limited. A Phase 2 trial for postoperative ileus was completed but failed to meet efficacy endpoints. No completed human trials have evaluated ipamorelin's effects on body composition, muscle mass, or recovery.
Research Status
Investigational Peptide — Not FDA Approved
Ipamorelin has no FDA-approved human product. The FDA recommended against adding ipamorelin to the 503A Bulks List in 2023, citing lack of safety and effectiveness data for subcutaneous administration. Outside of clinical research, the compound is available as a research chemical and is not intended for human use.
Ipamorelin 5 mg vs Other Axiolabs Preparations
Axiolabs offers several research peptides with distinct mechanisms. MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates metabolic pathways, while TB 500 contains a thymosin beta 4 fragment with actin-binding properties. GHK-CU is a copper-binding tripeptide with different research applications.
For GH axis research, Axiolabs also offers Sermorelin, a GHRH analog that stimulates GH release through a different receptor pathway. Ipamorelin's distinguishing characteristic among GH secretagogues is its selectivity profile, producing GH release without meaningful cortisol or prolactin elevation.
Dosage & Usage
Ipamorelin 5 mg Dosage & Usage
The information below is provided for educational reference only. Ipamorelin is a research peptide with no approved human dosing. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In non-medical bodybuilding and research contexts, ipamorelin is commonly referenced in the range of 200–300 mcg per injection, administered one to three times daily. Bedtime administration is frequently prioritized to coincide with the natural nocturnal GH surge. A minimum 2-hour fast before injection is widely recommended, as food intake blunts GH release.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Standard research protocol | 200–300 mcg per injection | 1–3 times daily, bedtime priority |
| Stacking with CJC-1295 (non-DAC) | 100–200 mcg Ipamorelin | Once or twice daily, combined injection |
| Cycle length (user-reported) | 8–12 weeks on | Followed by 4 weeks off |
These ranges represent community-reported practices and are not derived from completed human clinical trials. Human efficacy data for ipamorelin's GH-related effects is limited to animal studies.
Stacking & Cycle Considerations
In non-medical research discussions, ipamorelin is most commonly referenced in combination with a GHRH analog such as CJC-1295 (without DAC), targeting both the ghrelin receptor and the GHRH receptor for synergistic GH release. This stack is widely discussed in bodybuilding contexts as a foundation for GH-related research protocols.
Cycling protocols of 8–12 weeks on followed by 4 weeks off are the most commonly referenced community approach, though limited clinical data supports one cycling schedule over another. Cycling is intended to prevent receptor desensitization.
Managing Side Effects
Reported side effects in community use are generally mild and include injection site irritation, transient nausea (primarily during the first week), and occasional lightheadedness. The FDA's review of a clinical study noted hypokalemia and insomnia occurred more frequently in ipamorelin-treated subjects compared to placebo.
Because ipamorelin elevates GH and subsequently IGF-1, theoretical concerns regarding insulin sensitivity and growth-promoting effects exist. Blood glucose monitoring may be considered in extended research protocols.
Post-Cycle Therapy (PCT)
Ipamorelin is a peptide and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to ipamorelin in the context of hormonal recovery from steroid cycles. Research protocols typically include an off-cycle period to allow receptor resensitization.
Important
Individual Response Varies
Ipamorelin has no established human dosing for GH-related endpoints. Any information about non-medical use is derived from user-reported practices and is not validated by controlled clinical research. This information does not constitute medical advice.
Safety & Information
Ipamorelin Safety Information
Ipamorelin is a research compound with limited human safety data. No FDA-approved product exists, and the FDA has raised safety concerns regarding its use in compounding.
Important Safety Information
Ipamorelin is not approved for human use by the FDA. The compound is intended for research purposes only. The FDA has concluded that ipamorelin-related bulk drug substances may raise safety concerns based on available clinical information.
In a clinical study of ipamorelin for postoperative ileus, adverse events reported included hypokalemia, insomnia, hyperglycemia, nausea, vomiting, and abdominal distention. Two deaths occurred in ipamorelin-treated subjects, though it is unclear whether they were related to the drug.
Important
Non-Medical Use
Non-medical use of ipamorelin falls outside approved indications and carries unknown risks. Product purity does not establish that non-medical use is safe or appropriate for an individual.
Potential Adverse Effects
FDA review of available data identified the following potential adverse effects associated with ipamorelin: hypokalemia, insomnia, hyperglycemia, glucose intolerance, nausea, vomiting, and abdominal distention. The FDA also noted concerns about potential immunogenicity with subcutaneous administration due to peptide aggregation and impurities.
Because ipamorelin activates ghrelin receptors in brain regions associated with reward processing, the FDA has noted that the compound may have behavioral reinforcing properties that could contribute to addiction.
Elevated GH and IGF-1 levels may carry theoretical concerns regarding insulin sensitivity and growth-promoting effects, similar to other GH secretagogues.
Conditions Requiring Medical Evaluation
No formal contraindications exist for ipamorelin because no approved product exists. Precautionary considerations based on the compound's mechanisms include active malignancy or high cancer risk, uncontrolled diabetes or insulin resistance, pregnancy or breastfeeding, and cardiovascular disease requiring active management.
Competitive athletes should be aware that ipamorelin is prohibited by the World Anti-Doping Agency (WADA) under category S2 as a growth hormone secretagogue. Its use by athletes subject to anti-doping testing constitutes a doping violation.
Monitoring During Therapy
Because ipamorelin has no approved human therapeutic use, no standardized monitoring protocols exist. Research or non-medical use should be accompanied by awareness of the lack of established safety parameters. In community research protocols, bloodwork including IGF-1, fasting glucose, and insulin is sometimes recommended for monitoring purposes.
Product Care
Storage & Handling
Store the lyophilized powder under conditions appropriate for research peptides. Inspect the vial before use and do not use a product that appears damaged or compromised.
Keep all research compounds out of the reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Ipamorelin 5 mg is supplied through the official Axiolabs distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Axiolabs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Ipamorelin 5 mg product, use the security code on the vial label and cross-check it on the Axiolabs official site. Official Axiolabs presentation and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Ipamorelin 5 mg Storage
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Recommended Conditions
Store the lyophilized powder in a cool, dry place away from direct light. For long-term storage of lyophilized research peptides, refrigeration or freezing is commonly recommended to preserve stability. Once reconstituted, peptide solutions typically require refrigerated storage at 2–8°C and should be used within 14–21 days.
Keep the vial in its original packaging until use. Inspect the powder before reconstitution and avoid use if it appears discolored, clumped, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling practices when working with research compounds.
Quick Reference
Do & Don't
- Do store lyophilized powder in a cool, dry place
- Do refrigerate reconstituted solution at 2–8°C
- Do inspect before reconstitution
- Don't expose to direct sunlight or heat
- Don't use if powder appears discolored or clumped
- Don't freeze reconstituted peptide solutions
Frequently Asked Questions
Ipamorelin 5 mg FAQ
Answers to common questions about Ipamorelin 5 mg, the Ipamorelin peptide, and its research applications.
What is Ipamorelin 5 mg used for?
Ipamorelin 5 mg contains the selective growth hormone secretagogue ipamorelin. In research settings, ipamorelin has been studied for its ability to stimulate endogenous GH release through ghrelin receptor agonism. In non-medical bodybuilding contexts, it is commonly referenced for recovery, body composition, and sleep quality, though such use is not supported by completed human clinical trials and falls outside approved indications.
How often should Ipamorelin 5 mg be injected?
In non-medical research discussions, ipamorelin is commonly referenced at 200–300 mcg per injection, one to three times daily, with bedtime administration prioritized to coincide with the natural nocturnal GH surge. These figures represent community-reported practices and are not derived from controlled clinical trials.
Does Ipamorelin 5 mg require PCT?
Ipamorelin is a peptide and does not suppress endogenous testosterone production in the way anabolic steroids do. Post-cycle therapy is not applicable to ipamorelin in the context of hormonal recovery. Research protocols typically include an off-cycle period of 4 weeks following an 8–12 week active phase.
What does Ipamorelin do?
Ipamorelin is a selective growth hormone secretagogue that acts as a ghrelin receptor agonist. It stimulates the pituitary gland to release growth hormone in a pulsatile manner. Unlike older GHRPs such as GHRP-6, ipamorelin does not significantly elevate cortisol, prolactin, or appetite at doses that produce GH secretion.
How long does Ipamorelin take to work?
No established timeline exists for ipamorelin's effects in humans for GH-related endpoints. GH release occurs acutely after injection, but meaningful changes in body composition or recovery would require sustained use. The only completed human trial evaluated 7 days of treatment for postoperative ileus and did not assess GH-related outcomes.
Is Ipamorelin the best GH secretagogue?
There is no universally established "best" GH secretagogue, and ipamorelin has not been validated in completed human trials for GH-related outcomes. Its distinguishing characteristic is selectivity: it produces GH release without meaningful cortisol or prolactin elevation, which is why it has largely replaced GHRP-6 in modern research discussions.
What is the difference between Ipamorelin and Sermorelin?
Ipamorelin and Sermorelin work through different receptors. Ipamorelin is a ghrelin receptor agonist, while sermorelin is a GHRH analog that stimulates GH release through the GHRH receptor. In non-medical research discussions, ipamorelin is sometimes preferred for its selectivity profile, while sermorelin has a longer history of clinical use.
What is the difference between Ipamorelin and MOTS-c?
Ipamorelin and MOTS-c have fundamentally different mechanisms. Ipamorelin is a growth hormone secretagogue that stimulates GH release from the pituitary, while MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates metabolic pathways. They are investigated in different research contexts.
Is 200 mcg of Ipamorelin a lot?
Without established human dosing for GH-related endpoints, no microgram amount can be classified as appropriate or excessive. Ipamorelin 5 mg is labeled at 5 mg of lyophilized powder per vial. In non-medical research discussions, 200–300 mcg per injection is commonly referenced, but this does not establish validated dosing guidance.
What strength is Ipamorelin 5 mg?
Ipamorelin 5 mg is labeled at 5 mg of ipamorelin peptide per vial. It is supplied as a lyophilized powder in a 2 mL vial manufactured by Axiolabs.
Is Ipamorelin banned by WADA?
Yes. Ipamorelin is prohibited by the World Anti-Doping Agency (WADA) under category S2 as a growth hormone secretagogue. Its use by athletes subject to anti-doping testing constitutes a doping violation and has resulted in sanctions.
Related Offers
Axiolabs
Product Information Compound Details
Active Substance Tesamorelin Growth Hormone-Releasing Hormone (GHRH) Analog
5 mg/vialStrength 5 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Peptide Type GHRH Analog
Drug Class Research Peptide
Manufacturer Axiolabs
Axiolabs
Product Information Compound Details
Active Substance Sermorelin GHRH (1–29) Analog
5 mg/vialStrength 5 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Peptide Type GHRH Analog
Drug Class Research Peptide
Manufacturer Axiolabs
Axiolabs
Product Information Compound Details
Active Substance MOTS-c 16-Amino-Acid Mitochondrial-Derived Peptide
10 mg/vialStrength 10 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Peptide Type Mitochondrial-Derived Peptide
Drug Class Research Peptide
Manufacturer Axiolabs
Axiolabs
Product Information Compound Details
Active Substance GHK-Cu Copper Tripeptide-1 (Gly-His-Lys:Cu²⁺)
50 mg/vialStrength 50 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Peptide Type Copper-Binding Tripeptide
Drug Class Research Peptide
Manufacturer Axiolabs